Instil Bio, Inc. (TIL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 3.31M USD | Liabilities, Current |
| Cash and equivalents | 5.54M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.31M | $5.54M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $4.72M | $5.02M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $4.84M | $6.64M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $5.70M | $5.80M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $13.85M | $7.69M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.23M | $15.37M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $7.90M | $8.80M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $10.28M | $6.66M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $10.29M | $6.78M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $11.35M | $5.48M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $10.56M | $9.20M | $141.16M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $13.47M | $9.13M | $174.31M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $18.38M | $21.76M | $179.94M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $26.69M | $27.35M | $195.84M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $32.79M | $43.72M | $217.20M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $42.10M | $41.12M | $262.17M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $43.21M | $42.46M | $312.14M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $36.78M | $61.47M | $318.05M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $41.36M | $37.59M | $416.51M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $32.09M | $20.40M | $494.96M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $23.84M | $566.73M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $17.32M | $609.64M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $13.28M | $241.71M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |